Title: Muraglitazar
CAS Registry Number: 331741-94-7
CAS Name: N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine
Manufacturers' Codes: BMS-298585
Trademarks: Pargluva (BMS)
Molecular Formula: C29H28N2O7
Molecular Weight: 516.54
Percent Composition: C 67.43%, H 5.46%, N 5.42%, O 21.68%
Literature References: Peroxisome proliferator-activated receptor (PPAR) a/g dual agonist. Prepn: P. T. Cheng, WO 0121602; eidem, US 6414002 (2001, 2002 both to Bristol-Myers Squibb); P. V. Devasthale et al., J. Med. Chem. 48, 2248 (2005). Review of development and therapeutic potential: D. Barlocco, Curr. Opin. Invest. Drugs 6, 427-434 (2005).
Properties: Crystals from ethanol, mp 139.1-140.2°. uv max (methanol): 224, 277 nm.
Melting point: mp 139.1-140.2°
Absorption maximum: uv max (methanol): 224, 277 nm
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic.
Muramic Acid Muramyl Dipeptide Murexide Murexine Muromonab CD3

Systematic (IUPAC) name
Clinical data
Legal status  ?
CAS number 331741-94-7 YesY
ATC code None
PubChem CID 206044
KEGG D05091 YesY
Synonyms 2-[(4-Methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
Chemical data
Formula C29H28N2O7 
Mol. mass 516.54 g/mol
 N (what is this?)  (verify)

Muraglitazar (proposed tradename Pargluva) is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ.[1]

The drug had completed phase III clinical trials,[2] however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development.[3]

Data on muraglitazar is relatively less due to the recent introduction of this agent. One double-blind randomized clinical trial[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (P<0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase 2 and 3 clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and CHF when compared to placebo or pioglitazone.[4]